Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma

NCT04938297 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT04938297
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04938297 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma
Lead sponsor
Henan Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
May 26, 2021
Completion date
December 31, 2025
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system lymphoma